EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium–Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction

Mahesh M Umapathysivam iD, James Gunton, Steve N Stranks, David Jesudason

Diabetes Care · 01.01.2024 · 47 (1) · 140-143

DOI: 10.2337/dc23-1163 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Diabetes Care, online erschienen am 21.11.2023. Verfasst von Mahesh M Umapathysivam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Ketoacidosis, Sodium-Glucose Transporter 2 Inhibitors, Ketosis. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Ketoacidosis induced by sodium–glucose cotransporter 2 inhibitor (SGLT2i) treatment has been consistently observed in clinical practice in patients with type 2 diabetes despite minimal indication from the landmark cardiovascular outcome trials. It has been postulated that individuals without diabetes will not develop this complication due to an adequate insulin secretory capacity, which will protect against significant ketone formation. Cardiovascular outcome trials examining SGLT2i use in individuals with heart failure but not diabetes have not reported ketoacidosis. RESEARCH DESIGN AND METHODS We describe the first two case reports of severe nondiabetic ketoacidosis after initiation of an SGLT2i for the treatment of heart failure with reduced ejection fraction, and we describe the management strategies employed and implication for the pathophysiology of SGLT2i-associated ketoacidosis. RESULTS Each individual presented with ketoacidosis triggered by reduced oral nutrition intake. For both individuals, ketoacidosis resolved with intravenous glucose administration, encouragement of consumption of oral glucose-containing fluid, and minimal insulin administration. CONCLUSIONS These two cases demonstrate that SGLT2i-associated ketoacidosis is possible in individuals without diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Diabetic KetoacidosisSodium-Glucose Transporter 2 InhibitorsKetosisHeart FailureHumansHypoglycemic AgentsStroke VolumeInsulinGlucoseSodium

Substanzen

Hypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsInsulinGlucoseSodium

Autor:innen und Institutionen

  • Southern Adelaide Diabetes and Endocrine Services, Flinders Medical Centre, Adelaide, South Australia, Australia.
  • Endocrine Department, Queen Elizabeth Hospital, Woodville South, South Australia, Australia.
  • University of Adelaide, Adelaide, South Australia, Australia.
  • Basil Hetzel Institute, Woodville South, South Australia, Australia.
  • Flinders University, Adelaide, South Australia, Australia.
  • Department of Cardiovascular Medicine, Flinders Medical Centre, Adelaide, South Australia, Australia.

ORCID-Profile: Mahesh M Umapathysivam

Zitieren

APA

Umapathysivam, M. M., Gunton, J., Stranks, S. N., & Jesudason, D. (2024). Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium–Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction. Diabetes Care, 47(1), 140-143. https://doi.org/10.2337/dc23-1163

Vancouver

Umapathysivam MM, Gunton J, Stranks SN, Jesudason D. Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium–Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction. Diabetes Care. 2024;47(1):140-143. doi:10.2337/dc23-1163

BibTeX
@article{Umapathysivam2024,
  author = {Umapathysivam, Mahesh M and Gunton, James and Stranks, Steve N and Jesudason, David},
  title = {Euglycemic Ketoacidosis in Two Patients Without Diabetes After Introduction of Sodium–Glucose Cotransporter 2 Inhibitor for Heart Failure With Reduced Ejection Fraction},
  journal = {Diabetes Care},
  year = {2024},
  volume = {47},
  number = {1},
  pages = {140--143},
  doi = {10.2337/dc23-1163}
}
Kostenlos starten →